James K. Fong - Feb 28, 2022 Form 3 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
Senior Vice President and Chief Commercial Officer Exhibit 24 - Power of Attorney
Signature
/s/ Bruce J. Seeley, Attorney-in-fact for James K. Fong
Stock symbol
CTIC
Transactions as of
Feb 28, 2022
Transactions value $
$0
Form type
3
Date filed
3/11/2022, 06:37 PM
Next filing
Jan 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTIC Common Stock 3.57K Feb 28, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 360 $60.50 Direct F1
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 2.43K $35.70 Direct F2
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 3.7K $19.40 Direct F3
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 8.25K $4.48 Direct F4
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 10K $4.33 Direct F5
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 58.8K $3.19 Direct F6
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 23.3K $4.14 Direct F7
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 288K $0.95 Direct F8
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 210K $1.00 Direct F9
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 115K $3.30 Direct F10
holding CTIC Stock Option (right to buy) Feb 28, 2022 Common Stock 210K $3.05 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 360 shares of the Issuer's common stock and is fully vested.
F2 This option represents the right to purchase 2,430 shares of the Issuer's common stock and is fully vested.
F3 This option represents the right to purchase 3,700 shares of the Issuer's common stock and is fully vested.
F4 This option represents the right to purchase 8,250 shares of the Issuer's common stock and is fully vested.
F5 This option represents the right to purchase 10,000 shares of the Issuer's common stock and is fully vested.
F6 This option represents the right to purchase 58,750 shares of the Issuer's common stock and is fully vested.
F7 This option represents the right to purchase 23,340 shares of the Issuer's common stock and is fully vested.
F8 This option represents the right to purchase 288,000 shares of the Issuer's common stock and is fully vested.
F9 This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests in equal semi-annual installments beginning on September 11, 2020 through March 11, 2023, subject to the Reporting Person's continued service to the Issuer.
F10 This option represents the right to purchase 115,000 shares of the Issuer's common stock and vests in approximately equal semi-annual installments beginning on September 10, 2021 through March 10, 2024, subject to the Reporting Person's continued service to the Issuer.
F11 This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests 25% annually beginning on February 28, 2023, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Senior Vice President and Chief Commercial Officer Exhibit 24 - Power of Attorney